Evvy
Evvy offers an at-home metagenomic sequencing test of the vaginal microbiome. Licensed clinicians review the results and prescribe personalized treatment, and the company also sells a supplement and the EvvyAI assistant (launched May 2026). Revenue comes from direct-to-patient testing and care, and it is expanding through physician and partner channels. By September 2026 it had served more than 100,000 patients and 3,000 practitioners. It raised a $40M Series B led by Catalio Capital in September 2026, bringing total equity raised to about $59M. It is using its proprietary dataset to develop diagnostics, starting with fertility and IVF.
Funding
Every round, secondary, debt facility or acquisition involving Evvy that AI Lounge tracks, newest first. Latest: Series B on Sep 15, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in